News | October 27, 2025
Telangana targets Rs.1 lakh crore investments in Life Sciences by 2030
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries
Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India
Speakers for the Session are: Venkata Prasad K., Unit Head, Deepak Nitrite; Abhilash Pasham, Associate General Manager - Central Engineering & Projects, Dr. Reddy's Laboratories; C. V. Rajulu, Consultant, Industry; and Jyoti Shankar Jha, Senior Lead Scientist, Alleima India. The moderator for the Session is Pravin Prashant, Executive Editor, Indian Pharma Post
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Several technologies for hemoglobinopathies are being transferred to commercial partners
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
